Evidence map›Paper›PMID 36906636›Full record

ArticleActa neuropathologica communications2023

Different MAPT haplotypes influence expression of total MAPT in postmortem brain tissue.

Christina V Tauber, Sigrid C Schwarz, Thomas W Rösler, Thomas Arzberger, Steve Gentleman, Otto Windl, Mandy Krumbiegel, André Reis, Viktoria C Ruf, Jochen Herms and 1 more

Open access · goldFull text read
In one paragraph

Article in Acta neuropathologica communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Christina V Tauber *Department of Translational Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.ORCID 0000-0002-2970-877X
Sigrid C Schwarz *Department of Translational Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Thomas W RöslerDepartment of Translational Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Thomas ArzbergerCenter for Neuropathology and Prion Research, Ludwig-Maximilians University of Munich, Munich, Germany.
Steve GentlemanParkinson's UK Brain Bank, Department of Brain Sciences, Imperial College London, London, UK.
Otto WindlCenter for Neuropathology and Prion Research, Ludwig-Maximilians University of Munich, Munich, Germany.
Mandy KrumbiegelInstitute of Human Genetics, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
André ReisInstitute of Human Genetics, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Viktoria C RufCenter for Neuropathology and Prion Research, Ludwig-Maximilians University of Munich, Munich, Germany.
Jochen HermsCenter for Neuropathology and Prion Research, Ludwig-Maximilians University of Munich, Munich, Germany.
Günter U HöglingerDepartment of Translational Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. guenter.hoeglinger@med.uni-muenchen.de.
German Center for Neurodegenerative Diseases · DELudwig-Maximilians-Universität München · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEBrain Research UK · GBMunich Cluster for Systems Neurology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The MAPT gene, encoding the microtubule-associated protein tau on chromosome 17q21.31, is result of an inversion polymorphism, leading to two allelic variants (H1 and H2). Homozygosity for the more common haplotype H1 is associated with an increased risk for several tauopathies, but also for the synucleinopathy Parkinson's disease (PD). In the present study, we aimed to clarify whether the MAPT haplotype influences expression of MAPT and SNCA, encoding the protein α-synuclein (α-syn), on mRNA and protein levels in postmortem brains of PD patients and controls. We also investigated mRNA expression of several other MAPT haplotype-encoded genes. Postmortem tissues from cortex of fusiform gyrus (ctx-fg) and of the cerebellar hemisphere (ctx-cbl) of neuropathologically confirmed PD patients (n = 95) and age- and sex-matched controls (n = 81) were MAPT haplotype genotyped to identify cases homozygous for either H1 or H2. Relative expression of genes was quantified using real-time qPCR; soluble and insoluble protein levels of tau and α-syn were determined by Western blotting. Homozygosity for H1 versus H2 was associated with increased total MAPT mRNA expression in ctx-fg regardless of disease state. Inversely, H2 homozygosity was associated with markedly increased expression of the corresponding antisense MAPT-AS1 in ctx-cbl. PD patients had higher levels of insoluble 0N3R and 1N4R tau isoforms regardless of the MAPT genotype. The increased presence of insoluble α-syn in PD patients in ctx-fg validated the selected postmortem brain tissue. Our findings in this small, but well controlled cohort of PD and controls support a putative biological relevance of tau in PD. However, we did not identify any link between the disease-predisposing H1/H1 associated overexpression of MAPT with PD status. Further studies are required to gain a deeper understanding of the potential regulatory role of MAPT-AS1 and its association to the disease-protective H2/H2 condition in the context of PD.

Indexed as

Genetic Predisposition to DiseaseParkinson Diseasetau ProteinsBrainGenotypeHaplotypesHumansPolymorphism, Single NucleotideRNA, MessengerMAPT protein, humanRNA, Messengertau ProteinsGene expressionH1 and H2 haplotypeMAPTParkinson’s diseasePostmortem human brainProtein levelSynucleinsTau protein

Identifiers

PMID36906636
PMCPMC10008602
OpenAlexW4323923084

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read53
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.